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a b s t r a c t
Here we investigated the binding of Dengue virus envelope glycoprotein domain III (DIII) by two broadly
neutralizing antibodies (bNAbs), 4E11 and 4E5A. There are four serotypes of Dengue virus (DENV-1 to
-4), whose DIII sequences vary by up to 49%. We used combinatorial alanine scanning mutagenesis, a
phage display approach, to map functional epitopes (those residues that contribute most signiﬁcantly to
the energetics of antibody–antigen interaction) on these four serotypes. Our results showed that 4E11,
which binds strongly to DENV-1, -2, and -3, and moderately to DENV-4, recognized a common conserved
core functional epitope involving DIII residues K310, L/I387, L389, and W391. There were also unique
recognition features for each serotype, suggesting that 4E11 has ﬂexible recognition requirements.
Similar scanning studies for the related bNAb 4E5A, which binds more tightly to DENV-4, identiﬁed
broader functional epitopes on DENV-1. These results provide useful information for immunogen and
therapeutic antibody design.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The speciﬁc recognition of an antigen by an antibody is the
hallmark of humoral immunity; such interactions are essential for
the function of numerous antibody or antibody-like molecules for use
as therapeutic, diagnostic, or research reagents (French et al., 1989;
Milstein and Rada, 1995; Neuberger, 2002). Signiﬁcant effort has been
expended toward understanding the physicochemical basis of high
afﬁnity antibody-antigen interactions (Da Silva et al., 2010; Fellouse
et al., 2007; Fellouse et al., 2005; Fellouse et al., 2004; Persson et al.,
2013), how these interactions develop through the process of afﬁnity
maturation in naturally-occurring antibodies, (Li et al., 2003;
Wedemayer et al., 1997; Yin et al., 2003; Yin et al., 2001) and how
the information from these studies can be exploited for functional
design by combinatorial or computational protein engineering
(Fellouse et al., 2004; Persson et al., 2013; Tharakaraman et al., 2013).
An added layer of complexity is that some antibody combining
sites, natural or engineered, have “multispeciﬁc” properties in that
they are able to bind in high afﬁnity to multiple antigens with little or
no non-speciﬁc activity against irrelevant targets (Bostrom et al., 2011,
2009; Cockburn et al., 2012; Scheid et al., 2011; West et al., 2012; Wu
et al., 2011). For engineered bispeciﬁc antibodies, this expanded
recognition appears to require separate “functional paratopes” (i.e.,
those residues on the antibody combining site that contribute most to
the energy of the binding reaction) for each of the binding targets
(Bostrom et al., 2009, 2011). Prime examples of multispeciﬁc natural
antibodies are broadly neutralizing virus antibodies (bNAbs), which
are frequently derived from immunization or by mining antibody
repertoires of vaccinees or survivors and can bind to glycoproteins
with diverse primary sequences from different viral species or strains
(Bostrom et al., 2011, 2009; Cockburn et al., 2012; Scheid et al., 2011;
Wu et al., 2011). In general, bNAbs target conserved and sometimes
compact epitopes on viral glycoproteins (Ekiert et al., 2009; Wu et al.,
2011), but, in some cases, larger structural paratopes (antigen
contacting residues as determined from X-ray structures) engage
structural epitopes that include positions that contain high antigenic
diversity among viral strains or species (West et al., 2012). In several
viral systems including Dengue, HIV-1, and inﬂuenza, a wealth of
structural information on bNAb-glycoprotein complexes provides
some insight into the requisite features of the structural epitopes.
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However, less effort has been devoted toward understanding the
functional features (i.e., epitope residues that contribute most sig-
niﬁcantly to the energy of the bNAb–glycoprotein interaction) by
mutagenesis studies (Bedouelle et al., 2006; Lisova et al., 2007, 2014).
Here, we obtained comprehensive insight into functional epitope
requirements for recognition of Dengue virus (DENV) envelope glyco-
protein E domain III (DIII) by two related broadly neutralizing
antibodies, 4E11 and 4E5A, as a model system (Fig. 1) (Bedouelle
et al., 2006; Cockburn et al., 2012; Lisova et al., 2007, 2014;
Tharakaraman et al., 2013). There are four co-circulating serotypes of
Dengue virus (DENV-1, -2, -3, and -4), a mosquito-spread ﬂavivirus that
causes signiﬁcant disease in endemic subtropical regions (Dengue
Shock Syndrome, DSS, and Dengue Hemorrhagic Fever, DHF) (Gubler
et al., 2007; Halstead and O'rourke, 1977; Sangkawibha et al., 1984). A
particular challenge for DENV vaccine and immunotherapeutic devel-
opment is antibody-dependent enhancement of infection (ADE), a
phenomenon whereby serotype-speciﬁc antibodies resulting from a
primary infection worsen the severity of secondary infections caused
by other serotypes. In the current model for ADE, primary infection
results in a febrile illness and subsequent lifelong immunity against the
infecting serotype. However, antibodies from the primary infection are
weakly cross-reactive and non-neutralizing against the other serotypes
and lead to increased uptake of DENV by Fcγ-receptor positive cells
and thus increased viremia and pathology upon secondary infection
(Halstead and O'rourke, 1977; Sangkawibha et al., 1984). There is
signiﬁcant interest in identiﬁcation and characterization of potent
and broadly neutralizing antibodies, which would inhibit the infectious
cycle of all serotypes and prevent ADE.
A number of murine-derived DENV neutralizing antibodies, both
serotype-speciﬁc as well as bNAbs, target DIII. However, potent bNAbs
against other regions of the glycoprotein, such as the glycoprotein
prefusion dimer interface, arise during the course of natural human
infection (Austin et al., 2012; Beltramello et al., 2010; Brien et al.,
2010; Dejnirattisai et al., 2015; Edeling et al., 2014; Gentry et al., 1982;
Gromowski et al., 2010; Henchal et al., 1985; Kaufman et al., 1987; Li
et al., 2012; Lok et al., 2008; Megret et al., 1992; Roehrig et al., 1998;
Rouvinski et al., 2015; Shrestha et al., 2010; Sukupolvi-Petty et al.,
2007; Wahala and de Silva, 2011; Williams et al., 2012). Glycoprotein
E mediates entry into host cells and is located on the surface of the
virus in an array of 90 homodimers parallel to the virus membrane
(Fig. 1A) (Kuhn et al., 2002). The E ectodomain is composed of three
domains: domain I (DI) functions as a molecular hinge that links
domains II and III to one another, domain II (DII) is the dimerization
domain and contains the hydrophobic fusion loop necessary for virus
fusion with host cell endosomal membranes, and domain III (DIII) has
been implicated in receptor binding (Crill and Roehrig, 2001; Kuhn
et al., 2002; Rey et al., 1995). DIII connects to a stem region and the
transmembrane (TM) domain. After adsorption to host cells, DENV is
taken up via receptor-mediated endocytosis and infects through pH-
dependent virus membrane fusion in the late endosome (Harrison,
2008; van der Schaar et al., 2008; Zaitseva et al., 2010). Monoclonal
antibody (mAb) 4E11 is a murine antibody that was isolated from a
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Fig. 1. Structure of DENV DIII and library design. (A) Prefusion structure of homodimeric E, with the three domains on one of the subunits colored (DENV-2 shown as an
example, from PDB code 1OKE, Modis et al., 2003). (B) View of the DENV-2 DIII as an example down the 4E11 structural epitope. The A- and G-strands are labeled in the inset,
and the locations of the residues included in the combinatorial alanine scanning mutagenesis analysis are shown on the larger graphic, which has the same orientation as the
inset. Position 360 (not shown) was included in the analysis for DENV-2 only. (C) Overlay of the four DENV DIII domains bound to the 4E11 scFv (PDB codes 3UZQ, 3UZV,
3UZE, and 3UYP, Cockburn et al., 2012). (D) Amino acid alignment of the four DENV DIII domains. Residues that are absolutely conserved are colored red, those that are
conserved in three of the serotypes are colored blue. The location of the β-strands is indicated with arrows; the residues subjected to combinatorial scanning mutagenesis
are indicated with asterisks except for position 360 (^), which was analyzed in DENV-2 only.
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DENV-1 vaccinated mouse, binds to DIII and neutralizes all four
serotypes in vitro albeit with less afﬁnity and potency for DENV-4
(Cockburn et al., 2012; Megret et al., 1992). MAb 4E11 was subse-
quently used as a template for computational redesign to develop a
variant, 4E5A, with increased afﬁnity for DENV-4 while maintaining
afﬁnity across the other three serotypes. The bNAb 4E5A has a 45-fold
improved afﬁnity and 75-fold improved neutralization potency for
DENV-4 compared with 4E11 (Tharakaraman et al., 2013). In a recent
report, additional computational optimization of 4E5A yielded Ab513,
which exhibited further enhanced potency against DENV-4, was
neutralizing across broad genotypes within the four serotypes, and
was protective against clinical features of Dengue-related infections in
humanized mice (Robinson et al., 2015). Thus, there is considerable
interest in 4E11 and related mAbs as potential immunotherapeutic
agents.
Co-crystal structures of the 4E11 single chain variable fragment
(scFv) in complex with DIII from each serotype revealed that the mAb
binds in a similar location for all four serotypes (Fig. 1C), and that a key
aspect of recognition involves charge complementarity between the
4E11 paratope and DIII epitopes (Cockburn et al., 2012). Limited
scanning mutagenesis studies to dissect critical epitope-contributing
residues on DIII for binding and neutralization to these and other
related DIII mAbs have previously been described (Bedouelle et al.,
2006; Lisova et al., 2007). However, we sought to leverage the high-
throughput nature of combinatorial alanine scanning, a phage display
technique, to gain deeper insight into similarities and differences
among the recognition requirements for binding of 4E11 and 4E5A to
varying serotypes (Bogan and Thorn, 1998; Clackson and Wells, 1995;
Pál et al., 2005; Weiss et al., 2000). Furthermore, we sought to
correlate binding requirements with neutralization breadth for both
4E11 and 4E5A to understand if and how the hotspot proﬁle for
DENV-4 differs for bNAb 4E5A compared with that of 4E11. The results
reveal that recognition of DIIIs by 4E11 requires diverse functional
epitopes, but that there is a common conserved core. Furthermore,
4E5A has extended functional epitopes on both DENV-1 and -4 DIII in
comparison to 4E11, suggesting that its increased breadth requires
important interactions with a broader set of residues at the epitope
interface. These results provide information on the features that can
be required for broad recognition by antibodies, and reveal functional
details that can be used to help guide DENV DIII-based immunogen or
therapeutic antibody design.
Results
Combinatorial alanine scanning library design, construction, and
screening
DENV glycoprotein E DIII is a discretely folded β-sandwich
domain comprised of seven antiparallel β-strands (A–G) (Figs. 1B
and 1C) (Modis et al., 2003; Rey et al., 1995). Overall, the DIII
sequences among the serotypes are reasonably conserved, with
pairwise amino acid identities ranging from 51% to 70% and
similarities of 68–87% (Fig. 1D and Supplemental Information). The
minimal DIII sequences from all four serotypes were expressed
bivalently on M13 bacteriophage as fusions to the pIII coat protein
under the control of an alkaline phosphatase promoter. Included in
the display constructs were N-terminal FLAG epitopes, for detection
of display. Monoclonal phage ELISAs indicated that all four DIII
domains were expressed efﬁciently on phage, as detected by binding
to immobilized anti-FLAG antibody M2, and functionally, as detected
by binding to 4E11 (see Supplemental Information).
The reported X-ray structures of the DIII domain from all four
serotypes in complex with the single chain variable fragment (scFv) of
4E11 indicate that recognition of a lateral edge formed by the A and G
β-strands is a signiﬁcant component of 4E11-based recognition (Fig. 1B
and C) (Cockburn et al., 2012). Several other bNAbs, and some
serotype-speciﬁc mAbs also engage this epitope region, highlighting
its potential as a neutralization target (Austin et al., 2012; Brien et al.,
2010; Edeling et al., 2014; Gentry et al., 1982; Henchal et al., 1985;
Kaufman et al., 1987; Li et al., 2012; Lok et al., 2008; Shrestha et al.,
2010; Sukupolvi-Petty et al., 2007). Based on inspection of the 4E11
scFv-DIII complexes, 22 residues on DENV-1, -3 and -4 DIII and 23
residues on DENV-2 DIII were chosen for analysis via combinatorial
alanine scanning (Figs. 1B and 1D). Combinatorial alanine scanning is a
high-throughput phage display method to determine energetic con-
tributions of residues to intermolecular interactions (Weiss et al.,
2000). In this approach, limited diversity phage libraries are produced
inwhich the contact residues are allowed to vary betweenWTand Ala
(in some cases, additional diversity is permitted due to the degeneracy
of the genetic code). The “alanine scanning” libraries are subjected to
selection against the target, here, 4E11 or 4E5A. The resulting popula-
tion of ELISA-positive clones is analyzed for positional bias towardWT,
indicative of a strong requirement for the WT side chain in binding. A
parallel selection is performed to correct for display bias, here against
anti-FLAG antibody M2 (a FLAG epitope is included at the N-terminus
of the displayed DIIIs). The ratio of observed WT residues to Ala (WT/
Ala) at any particular position can be determined and used to
approximate the ratio of the association constants of WT and a
WT-Ala mutant. Therefore, an energetic value can be computed
and assigned for contribution of each residue to binding energy based
on the sequencing data (ΔΔGAla–WT). This method allows for the rapid
dissection of intermolecular interfaces; its high-throughput nature
allows computation of ΔΔGAla–WT values for many more positions
than is practical by traditional site-directed mutagenesis. Importantly,
the results from combinatorial alanine scanning have been closely
correlated with traditional mutagenesis studies in several systems (Da
Silva et al., 2010; Pál et al., 2005; Vajdos et al., 2002; Weiss et al.,
2000).
The residues chosen for analysis on DENV DIIIs included both
direct contact residues (structural epitope), as deﬁned by a 4.5 Å
cutoff, but also residues that potentially played supporting con-
formational roles. About 29% of the mutagenized residues were
conserved among all four serotypes. Limited diversity phage display
libraries were constructed (two libraries/serotype) using the rando-
mization scheme of Weiss et al., which allows variation among WT
and Ala with additional diversity (3rd or 4th residues) at some
positions due to the degeneracy of the genetic code (Weiss et al.,
2000). All libraries were produced with sizes of 108 clones or
higher, exceeding the theoretical diversities by 100-fold or more
thus ensuring adequate sampling of sequence space. Combinatorial
alanine scanning libraries were each screened in parallel against
both 4E11 (functional selection) and M2 (display selection). As
described previously, the sequencing of ELISA-positive output
populations from these was used to approximate energetic con-
tributions to the intermolecular interface (ΔΔGAla–WT) (Pál et al.,
2005; Weiss et al., 2000). The critical assumption in this analysis is
that the ratio of WT to Ala (WT/Ala) in the selected sequence
population is proportional to the ratio of the association constants
of the WT protein and a WT-Ala point mutant (Weiss et al., 2000).
Since display biases may be inherent for certain residues at
particular positions or for some sequences, normalization for dis-
play via the M2 selection is a critical component of this analysis. The
4E11-selected populations contained a high percentage of clones
with strong, positive and selective binding signals toward 4E11
(450% of the clones had monoclonal phage ELISA signals greater
than 5-fold over background wells containing BSA). The sequences
of the 4E11- and M2-selected clones were diverse in nature, though
some siblings were apparent in the 4E11-selected populations. In
the most abundant cases, a single sibling constituted 5% of the
overall population of selected clones.
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Table 1 shows the numerical results of the sequence
analysis from 60 to 157 clones per selection; these data are
represented graphically, with the surface of the DIII structure
color coded according to measured ΔΔGAla–WT values, in
Fig. 2. Screening of the DENV-4 structural epitope was incom-
plete because one of the two libraries, covering the “lower”
portion of the epitope, was inefﬁcient. Only one ELISA-positive
sequence was identiﬁed from screening of approximately 200
clones from this library, and this clone maintained seven WT
residues out of eleven varied structural epitope positions. This
result suggests that mutations at these positions are not
tolerated, likely because the binding of 4E11 to DENV-4 DIII
is 4500-fold weaker than for DENV-1-3 (reported KD of
4.1 μM compared to 0.08–8 nM) (Cockburn et al., 2012). Thus,
even minor perturbations in this C-terminal portion of the
structural epitope cause a complete lack of binding and there-
fore very few members of the library contain functional
activity. Among all positions for which data could be derived,
the measured ΔΔGAla–WT values spanned a large range, with
negative values at some positions, indicating a preference for
Ala over WT. Numerous “hot spot” residues were identiﬁed on
each serotype, deﬁned here as ΔΔGAla–WT41.0 kcal/mol, and
Table 1
Combinatorial alanine scanning results against 4E11a.
Res. DENV-1 DIIIb Res. DENV-2 DIIIb
WT/Ala
(4E11)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
WT/Ala
(4E11)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
S305 1.0 1.4 0.18 – – K305 5.7 2.3 0.54 0.63 (E) 0.54 (T)
K307 4.6 3.9 0.10 0.40 (E) 0.0 (T) K307 35 2.2 1.7 1.9 (E) 0.67 (T)
L308 4.6 3.6 0.15 0.14 (P) 0.03 (V) I308 15 4.7 0.70 0.65 (T) 0.45 (V)
E309 1.5 1.4 0.04 – – V309 1.7 2.4 0.21 – –
K310 24 3.2 1.2 1.7 (E) 0.47 (T) K310 11 1.9 1.0 1.6 (E) 0.90 (T)
E311 1.5 2.8 0.36 – – E311 2.3 2.0 0.07 – –
V312 2.7 1.6 0.29 – – I312 20 1.8 1.4 1.5 (T) 0.46 (V)
Q323 2.8 1.5 0.39 0.50 (E) 0.24 (P) R323 0.64 0.94 0.23 -0.79 (G) -0.86 (P)
K325 3.9 2.6 0.23 1.3 (E) -1.0 (T) Q325 1.9 1.7 0.07 -0.5 (E) 42.6 (P)C
E327 2.3 3.0 0.16 – – E327 6.0 1.5 0.84 – –
P332 40 5.1 1.2 – – P332 52 0.90 2.4 – –
E360 2.1 1.5 0.22 – –
K361 2.2 5.5 -0.55 -0.08 (E) 0.03 (T) K361 1.5 0.94 0.27 0.91 (E) 0.39 (T)
E362 1.5 1.8 -0.12 – – D362 1.9 1.7 0.05 – –
P364 0.77 0.99 -0.15 – – P364 1.1 0.75 0.24 – –
N366 0.95 1.9 -0.41 -0.42 (D) 0.07 (T) N366 2.3 2.5 -0.05 0.25 (D) 0.24 (T)
E384 2.4 2.3 0.01 - - P384 7.0 0.60 1.5 - -
K385 2.9 2.2 0.16 0.36 (E) 0.13 (T) G385 1.4 2.4 0.31 - -
L387 18 2.6 1.1 1.2 (P) 0.15 (V) L387 12 0.88 1.6 42.7 (P)C 0.50 (V)
K388 2.6 1.3 0.41 0.80 (E) 0.36 (T) K388 0.95 1.0 0.03 0.53 (E) 0.02 (T)
L389 8.9 2.0 0.89 2.0 (P) 0.23 (V) L389 14 1.0 1.6 42.5 (P)C 0.39 (V)
S390 1.5 1.1 0.18 – – N390 2.2 1.5 0.25 1.4 (D) 0.14 (T)
W391 5.2 1.6 0.69 0.67 (G) 0.34 (S) W391 77 1.2 2.5 3.4 (G) 2.4 (S)
DENV-3 DIIIb DENV-4 DIIIb
WT/Ala
(4E11)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
WT/Ala
(4E11)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
T305 0.83 0.77 0.04 – – K305 4.7 2.1 0.49 0.92 (E) 0.09 (T)
V307 4.2 2.7 0.25 – – S307 78 6.9 1.5 – –
L308 32 5.9 1.0 41.6 (P)C 1.3 (V) I308 4121 18 41.2 C 41.7 (T )C 0.39 (V)
K309 0.39 1.3 0.70 0.22 (E) 0.35 (T) D309 0.01 0.58 -2.3 – –
K310 6.4 2.8 0.51 1.2 (E) 0.21 (T) K310 157 4.8 2.1 43.5 (E)C 4 28 (T)C
E311 3.0 1.6 0.38 – – E311 5.1 3.0 0.31 – –
V312 16 5.3 0.67 – – M312 10 5.0 0.43 41.7 (T)C 0.17 (V)
K323 8.5 3.1 0.60 -0.50 (E) -0.64 (T) K323 NDd
E325 22 7.8 0.62 – – K325 NDd
K327 52 2.5 1.8 42.8 (E) C 1.2 (T) E327 NDd
P332 4114 1.1 42.8 C – – P332 NDd
K361 1.4 1.2 0.08 0.59 (E) 0.25 (T) T361 3.6 2.3 0.28 - -
E362 2.0 2.4 0.11 – – N362 3.6 3.4 0.03 0.29 (D) 0.10 (T)
P364 0.95 0.68 0.20 – – V364 6.5 4.4 0.23 - -
N366 1.1 1.7 0.27 0.16 (D) 0.35 (T) N366 1.1 0.60 0.37 0.42 (D) 0.19 (T)
D384 1.2 1.7 0.21 – – D384 NDd
K385 5.8 3.1 0.38 0.70 (E) 0.89 (T) S385 NDd
L387 4110 1.5 42.6C 42.4 (P)C 2.0 (V) L387 NDd
K388 33 1.1 2.0 42.8 (E)C 1.3 (T) T388 NDd
I389 493 1.8 42.4 C 42.1 (T)C 0.77 (V) L389 NDd
N390 1.7 1.2 0.22 1.3 (D) 1.6 (T) H390 NDd
W391 16 1.2 1.6 2.0 (G) 1.5 (S) W391 NDd
a Calculated WT/Ala ratios for 4E11 and M2 and ΔΔGAla–WT are listed. In cases where additional residues were permitted, the ΔΔGm2–WT and ΔΔGm3–WT values are also
provided. Mutations that were largely deleterious (Z1 kcal/mol) are shown in bold.
b Sample sizes were greater than 100 in most cases (see Supporting Information).
c In some cases, a single sequence containing a mutation was not isolated in the selected pool, therefore only a lower estimate could be provided.
d Not determined. Values for positions located in the “lower” segment of the DENV-4 DIII epitope could not be obtained due to inefﬁcient library screening.
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in several cases WT was absolutely conserved over Ala, allow-
ing only a lower estimate of the value for ΔΔGAla–WT.
Comparison of functional epitopes across DENV serotypes for
recognition by 4E11
Fig. 2 shows that the topological landscape of the functional
epitopes varies among the four serotypes. For example, only two
residues on DENV-1 DIII were “hot spot” positions, K310 on the A-
strand and L387 on the G-strand. Residues L389 and W391 on the
G-strand contributed less signiﬁcantly (0.5–1 kcal/mol) but
together with K310 and L387 form a nearly contiguous and mostly
hydrophobic core epitope. By contrast, the functional epitopes on
DENV-2 and DENV-3 are more extended in nature with additional
contributing residues from the A- and G-strands. In addition to the
conserved K310 and L387 as observed with DENV-1, the hotspot
residues in DENV-2 include K307, I312, L389, and W391 with
signiﬁcant but smaller contributions from K305 and E327. In
DENV-3, hot spot residues include L308, K327, L387, K388, I389,
and W391; residue K310 contributed more moderately as did
V312, K323, and E325. In addition, P332, which was not a direct
contact residue but appeared to possibly play a supporting
structural role, was strongly preferred in DENV-1, -2, and -3. The
lower half of the structural epitope on DENV-4 could not be
scanned, including the G-strand, but among those assayed, A-
strand residues S307, I308, and K310 were all hot spot residues.
Despite these differences, there appear to be some similarities
among the contributing functional epitopes. Residues K310 (A-
strand) and residues L387, L389 (I389 in DENV-3), and W391 from
the G-strand form a “core functional epitope” that contributes
signiﬁcantly to binding in DENV-1-3. Additionally, K310 on DENV-4
was shown to be important for recognition, from the limited
scanning results. The core functional epitope residues are conserved
across the four serotypes, except for a relatively conservative L-I
substitution at position 389 in DENV-3, and likely function as a
critical recognition motif for 4E11. The quantiﬁedΔΔGAla–WT for core
functional epitope residues is higher than 1 kcal/mol in most cases.
Values for L389 and W391 were below this threshold in DENV-1
(0.89 and 0.69 kcal/mol, respectively) as was K310 in DENV-3
(0.51 kcal/mol) but these side chains nonetheless contributed sig-
niﬁcantly to the interaction; notably, L387 and I389 were completely
intolerant to Ala substitution in DENV-3. At all four core functional
epitope positions, the combinatorial alanine scanning randomization
scheme allowed for third and fourth side chain variants, many of
which were also poorly tolerated. For example, a K310E mutation
was disfavored in all four serotypes, with ΔΔGm2–WT values greater
than 1 kcal/mol in all cases; accommodation of a K310T mutation
varied across serotypes. Mutations L387P and L389P were strongly
destabilizing, with Pro not observed in any selected clones at either
position in DENV-2 and DENV-3. The more conservative L387V and
L389V mutations were accommodated to various degrees in DENV-1,
-2, and -3 with DENV-3 being the most stringent. AW391Gmutation
was poorly tolerated in DENV-1, -2, and -3 with ΔΔGm2–WT higher
than 1 kcal/mol in the latter two; a W391S mutation was somewhat
destabilizing in DENV-1 but signiﬁcantly destabilizing in DENV-2 and
DENV-3.
In addition to the core functional epitope, each serotype also
contains unique hot spots that are only partially conserved across
the serotypes and lie outside of a central hydrophobic patch made
up of the A- and G-strands (Cockburn et al., 2012). K307 (S307 in
DENV-4) is a hotspot only in DENV-2 and -4, while residue I312 is
unique to DENV-3 as are residues K327 and K388 for DENV-3.
L308 in DENV-3 and the corresponding I308 in DENV-4 were
hotspot residues, the corresponding positions were less important
in DENV-2 (I308) and DENV-1 (L308). These results suggest that
4E11 binding involves recognition of the core functional epitope,
but that 4E11 is ultimately ﬂexible in its binding requirements to
allow broad and tight recognition across DENV-1 to -3. Certain
Fig. 2. Heat maps of functional epitopes on DENV-1 through -4 for 4E11 binding color-coded based on observed ΔΔGAla–WT values. Residues in DENV-4 that could not be
mapped are shown as dark gray. A conserved, core functional epitope is comprised of K310, L/I387, L389, and W391. In addition, recognition features unique to each serotype
were also observed.
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aspects of this recognition appear to be important for recognition
by DENV-4.
Relation to previously reported site-directed mutagenesis studies
The novelty of the current study relative to previous work lies in
the high-throughput nature of the combinatorial alanine scanning
method, which allowed comprehensive analysis of thermodynamic
contributions for nearly all 4E11 structural epitope residues in the
four DENV serotypes. Previously reported site-directed mutagenesis
studies on this interaction focused only on a single serotype (DENV-
1) and a subset of residues (Bedouelle et al., 2006; Lisova et al.,
2007, 2014). An important aspect of combinatorial alanine scanning
is benchmarking to previous site-directed mutagenesis studies
when available. For example, the ΔΔGAla–WT values from combi-
natorial alanine scanning and traditional site-directed mutagenesis
studies correlate closely in the case of hGH–hGHR, and to lesser
extents in other systems (Clackson and Wells, 1995; Da Silva et al.,
2010; Pál et al., 2005; Weiss et al., 2000). We therefore compared
our alanine scanning results with previously published mutagenesis
data by Bedouelle and coworkers for DENV-1 DIII in which
individual DIII alanine mutants were puriﬁed and tested for their
binding afﬁnities for 4E11 (Bedouelle et al., 2006; Lisova et al., 2007,
2014). The Bedouelle study encompassed 14 total A/G-strand
residues, 11 of which overlapped with our subset, and three of
which are not included in our analysis. Overall, the range of positive
ΔΔGAla–WT values obtained by combinatorial scanning mutagenesis
was smaller than those previously reported by site-directed muta-
genesis studies. Bedouelle and coworkers deﬁned “hot spot” posi-
tions as those with ΔΔGAla–WT41.5 kcal/mol whereas we, and
others who have utilized combinatorial alanine scanning, have
deﬁned hot spot positions as41.0 kcal/mol.
Residues K307, L308, K310, and L389 were identiﬁed as hot spot
residues with ΔΔGAla–WT values ranging from 1.8 to 5.1 kcal/mol
by Bedouelle and coworkers (Lisova et al., 2007). Residues K310
and L389 were also important in combinatorial alanine scanning
(ΔΔGAla–WT of 1.2 and 0.9 kcal/mol, with L389 falling just below
the hot spot cutoff) but K307 and L308 were less important
(ΔΔGAla–WT of 0.1 and 0.2 kcal/mol). A possible explanation for
the discrepancy of ΔΔGAla–WT values at K307 and L308 reported
here and in the Bedouelle studies is that WT-Ala mutations are
deleterious to folding; we observed elevated WT/Ala ratios in both
the functional (4E11) and display (M2) selections. Display efﬁ-
ciency of a protein is thought to be linked to folding stability and
thus high WT/Ala ratios in the display selection may be indicative
of defects in folding (Weiss et al., 2000). However, we note that the
range of elevated WT/Ala ratios we observed, 3.6–4.6, were much
more muted than the preference that would result in ΔΔGAla–WT
values observed in the Bedouelle site-directed mutagenesis study
(2.2 and 1.1 kcal/mol, respectively, which corresponds to 7- and
50-fold preferences in KD).
Although below their hot spot cutoff, E309A and V312A were
also destabilizing (1.1 and 1.3 kcal/mol) in the Bedouelle studies.
However, from our analysis, ΔΔGAla–WT values at these positions
by combinatorial alanine scanning were lower (0.04 and 0.29 kcal/
mol). To further explore the contribution of these two residues, we
prepared individual site-directed E309A and V312A point mutants
of phage-expressed DIII. A competition ELISA was performed, in
which the capacity of phage-expressed DENV-1 (WT and mutants)
to bind immobilized 4E11 in the presence of increasing amounts of
soluble WT DENV-1 DIII was examined (Fig. 3A). It is expected
that, if a particular point mutant has drastically decreased binding
afﬁnity for 4E11 relative to WT, then those phage would be much
more effectively competed for binding by soluble WT DENV-1 DIII
protein than the WT DENV-1 DIII expressing phage. The IC50
values from this analysis indicated only minor differences between
WT and E309A DENV-1 DIII phage (3.1 μM vs. 1.4 μM), and a
stronger but still moderate effect for the V312A mutant (0.3 μM).
These results are internally consistent with the combinatorial
alanine scanning results that suggest E309A has no perturbing
effect on binding, and V312A has an intermediate effect. The
reasons for the discrepancy in our results with those of Bedouelle
and coworkers are not immediately obvious. However, the overall
comparisons among combinatorial scanning data and previously
published data suggest that strong hot spots, that do not affect
display efﬁciency, can be identiﬁed with strong correlation by
combinatorial scanning mutagenesis.
On DENV-1, L387A and W391A mutations were found deleterious
for binding in site-directed mutagenesis studies, in agreement with
our studies, but the ΔΔGAla–WT values varied slightly in the previous
report (0.7 and 1.2 kcal/mol, respectively) than those observed here
(1.1 and 0.7 kcal/mol, respectively). Notably, these two positions form
part of the “core functional epitope” and were much more strongly
preferred in DENV-2 and -3 (ΔΔGAla–WT41 kcal/mol). To further
explore the role of these mutations, and to further validate the
combinatorial scanning mutagenesis data in DENV-2, where previous
site directed mutagenesis data are not available, we prepared
individual WT-Ala variants at these positions in DENV-2 DIII on
phage and performed competitive phage ELISA with soluble, WT
DENV-2 DIII protein (Fig. 3B). Soluble WT DENV-2 DIII protein
competed with binding of WT DENV-2 DIII phage, as expected, with
an IC50 of 4.1 μM. However, both L387A and W391A DIII phage were
competed much more effectively by soluble WT DENV-2 DIII protein,
with IC50 values 40-fold lower. The higher capacity of WT DENV-2
DIII protein to compete the DENV-2 DIII L387A and W391A phage
relative to WT DENV-2 DIII phage indicate that the afﬁnity for these
two point mutants is much lower thanWT DENV-2 DIII for binding to
4E11 and support conclusions by combinatorial scanning mutagenesis
that these DENV-2 DIII residues are critical for binding 4E11.
Our analysis further identiﬁed residue P332 as a strong hot spot
residue in DENV-1 (ΔΔGAla–WT of 1.2 kcal/mol). A P332A mutation
was not previously assayed by site-directed mutagenesis studies
for 4E11, as it lies in the turn region between the B and C strands
and does not make direct contact with 4E11. However, P332A
mutation was assayed previously by site-directed mutagenesis
studies against a similar antibody, 1A1D-2, and found to be
important for binding in that interaction (Gromowski et al.,
2010). Furthermore, P332 appears to play a critical supporting
role for DIII recognition by 4E11 as it is both conserved and had a
high ΔΔGAla–WT value for DENV-1, -2, and -3 by our analysis (this
residue could not be scanned in DENV-4).
Comparison of functional epitopes on DENV-1 and DENV-4 for
recognition by 4E5A
Antibody 4E5A is a computationally designed variant of 4E11
that has higher binding and neutralization activity against DENV-4
while retaining strong activity against DENV-1, -2, and -3
(Tharakaraman et al., 2013). The sequence of 4E5A differs from
4E11 at one heavy chain position and four light chain positions
(Tharakaraman et al., 2013). The difference in activity between
4E11, which binds and effectively neutralizes DENV-1, -2, and -3
but has more modest activity against DENV-4, and 4E5A, which is
potent against all four serotypes, provides an opportunity to
explore whether functional epitopes vary among similar bNAbs
that vary in the breadth of their activity. The combinatorial alanine
scanning analysis was performed for DENV-1 and DENV-4 DIII
against 4E5A (Fig. 4). In contrast to 4E11, the selection of DENV-4
DIII alanine scanning libraries proceeded efﬁciently and therefore
the functional epitope could be mapped to completion for both
DENV-1 and DENV-4. It is possible that complete scanning for
DENV-4 against 4E5A was efﬁcient because it has 45-fold higher
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afﬁnity than 4E11, thus individual WT-Ala mutations were
tolerated enough to allow analysis in this case. The results from
this analysis are shown numerically in Table 2 and graphically in
Fig. 4.
Comparison of DENV-1 functional epitopes for 4E11 and 4E5A
indicates that the 4E5A functional epitope is larger and more
extended for at least DENV-1, with L308 and K388 playing stronger
roles in the 4E5A interaction. The 4E5A epitope contains fewer
Fig. 3. Validation of combinatorial alanine scanning results for DENV-1 (A) and DENV-2 (B) point mutants by competition phage ELISA. (A) Competition of phage expressing
WT, E309A, and V312A DENV-1 DIII for binding to immobilized 4E11 by soluble WT DENV-1 DIII protein. (B) Similar analysis for WT, L387A, and W391A DENV-2 DIII
expressing phage for competition against soluble WT DENV-2 DIII protein.
Fig. 4. Heat maps of functional epitopes on DENV-1 and -4 for 4E5A binding color-coded based on observed ΔΔGAla–WT values. For both serotypes, an extended functional
epitope was observed in comparison to 4E11.
Table 2
Combinatorial alanine scanning results against 4E5A.
Res. DENV-1 DIII Res. DENV-4 DIII
WT/Ala
(4E5A)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
WT/Ala
(4E5A)
WT/Ala
(M2)
ΔΔGAla–WT
(kcal/mol)
ΔΔGm2–WT
(kcal/mol)
ΔΔGm3–WT
(kcal/mol)
S305 0.92 1.4 0.26 – – K305 13 2.1 1.1 1.4 (E) 1.2 (T)
K307 6.0 3.9 0.27 0.53 (E) 0.34 (T) S307 20 6.9 0.63 – –
L308 35 3.6 1.4 0.73 (P) 0.23 (V) I308 4 78 18 40.89a 1.0 (T) 0.41 (V)
E309 1.0 1.4 0.20 – – D309 0.05 0.58 1.5 – –
K310 44 3.2 1.6 2.0 (E) 1.0 (T) K310 100 4.8 1.8 43.2 (E) 2.1 (T)
E311 2.0 2.8 0.20 – – E311 16 3.0 1.0 – –
V312 2.0 1.6 0.12 – – M312 19 5.0 0.79 1.6 (T) 0.28 (V)
Q323 2.2 1.5 0.23 0.67 (E) 0.00 (P) K323 5.8 3.2 0.36 – –
K325 5.5 2.6 0.45 0.06 (E) 0.19 (T) K325 61 3.9 1.6 1.7 (E) 0.73 (T)
E327 2.9 3.0 0.02 – – E327 1.5 2.2 0.23 – –
P332 4.7 5.1 0.05 – – P332 4 75 1.0 41.5 – –
K361 5.5 5.5 0.00 0.28 (E) 0.02 (T) T361 5.4 2.3 0.52 – –
E362 1.3 1.8 0.21 – – N362 5.9 3.4 0.32 0.02 (D) 0.51 (T)
P364 0.66 0.99 0.25 – – V364 14 4.4 0.68 – –
N366 0.79 1.9 0.52 0.05 (D) 0.11 (T) N366 0.82 0.60 0.19 0.31 (D) 0.39 (T)
E384 2.6 2.3 0.08 – – D384 2.6 3.0 0.10 – –
K385 2.9 2.2 0.15 0.67 (E) 0.04 (T) S385 3.4 2.5 0.19 – –
L387 8.8 2.6 0.72 0.93 (P) 0.38 (V) L387 17 0.98 1.7 41.6 (P) 0.82 (V)
K388 4.3 1.3 0.72 0.75 (E) 1.0 (T) T388 2.4 1.4 0.30 – –
L389 7.0 2.0 0.75 0.67 (P) 0.15 (V) L389 4 52 2.7 4 1.8 41.9 (P) 0.38 (V)
S390 1.4 1.1 0.13 – – H390 21 1.8 1.5 2.4 (D) 0.62 (P)
W391 5.5 1.6 0.72 0.45 (G) 0.35 (S) W391 14 2.4 1.1 2.5 (G) 0.88 (S)
a A lower estimate only for ΔΔGAla–WT could be obtained for I308, because no Ala mutations were observed in the selected pool. Although the calculated lower estimate
falls below the “hot spot” threshold, this residue was classiﬁed nonetheless as a hot spot due to the clear preference for WT over Ala in the 4E5A binding selection.
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residues that meet the criteria of a hot spot (ΔΔGAla–WT41 kcal/
mol) than 4E11, but several additional residues had contribu-
tions40.5 kcal/mol. The analysis also revealed a total of 10 hot spot
residues for DENV-4 DIII recognition by 4E5A, four of which were
also part of the partially mapped functional epitope of 4E11. In line
with the higher afﬁnity of 4E5A for DENV-4 DIII, we found that 4E5A
requires extended interactions involving many residues on both the
A- and G-strands. All four residues from the core functional epitope
of 4E11 were also required for recognition of both DENV-1 and
DENV-4 by 4E5A. Together, these results suggest that both bNAbs
recognize similar features across the different serotypes, but that key
mutations within 4E5A increase favorable interactions with DENV-4
DIII while maintaining afﬁnity across the other three serotypes.
Discussion
Co-crystal structures of DIII from all four serotypes in complex
with the 4E11 scFv suggested that the strictly conserved, charged
residues K310 and E311 are important for antibody-antigen recogni-
tion across the four serotypes (Cockburn et al., 2012). In partial
agreement with these conclusions, our mutagenesis data revealed
that K310 is critically important for the binding energetics and
recognition of 4E11 across the four serotypes as it was identiﬁed as
a hotspot with ΔΔGAla-WT41 kcal/mol for three of the serotypes
(DENV-1, -2, -4). However, the requirement for E311 was not evident
from our analysis, as this position did not have highΔΔGAla–WT values
for any of the serotypes. From the crystallographic studies, it was
postulated that bNAb 4E11 recognizes DIII from all four serotypes by
ﬂexibly binding to DIII in order to partially conserve charge comple-
mentarity between the paratope and epitope. The charge comple-
mentarity is maintained by adjacent patches of positive and negative
charge that arise from CDR-H2 residue ArgH94 and CDR-L3 residue
GluL55 in the 4E11 paratope (Cockburn et al., 2012). Supporting
evidence for this hypothesis is evident in the co-crystal structure of
DENV-3, in which the overall positioning of 4E11 in relation to DIII is
shifted, so that the charged side chains of ArgH94 and GluL55 interact
with the B-strand residues E325 and K327 on DENV-3 DIII to conserve
charge complementarity across the paratope-epitope. Interestingly,
our mutagenesis data correlates with this, as E325 and K327 were
both signiﬁcant contributors to binding of 4E11 to DENV-3 DIII, a
unique feature that was not observed in DENV-1 and -2 (Fig. 2).
Our results suggest that broad recognition for at least DENV-1, -2,
and -3 requires recognition of a common conserved functional epitope
core consisting of K310, L387, L/I389, and W391. Requirements for
DENV-2 and -3 appear more stringent than DENV-1, as indicated by
the broader contiguous residues with strong ΔΔGAla–WT values. The
ΔΔGAla–WT values obtained by combinatorial scanning mutagenesis
reliably identiﬁed strongly contributing residues and were internally
consistent with competitive ELISA experiments with speciﬁc single
point mutations in DENV-1 and DENV-2 DIII. A limitation of combi-
natorial scanning mutagenesis is the fact that it does not allow for
error estimates within a given dataset, but this is mitigated by the
rapidity with which functional data can be obtained. The analysis
provided here, which involved assays for 89 total residues across four
different DIII variants, and against two different antibodies, under-
scores the utility of the approach for obtaining large datasets.
Individual puriﬁcation and characterization of single point mutants
to obtain this level of insight is laborious and not practical for most
laboratories. The analysis reported here also augments previous
studies employing less comprehensive analysis of epitope residues
on DENV-1 DIII for 4E11 or DENV-2 DIII for the related antibody
1A1D-2 (Gromowski et al., 2010; Lisova et al., 2007). The novel
conclusions from our analysis are that the core functional epitope
exists for DENV-1 through -3, but that broad recognition also relies on
subtle differences among the serotypes. For example, DENV-2 and
DENV-3 functional epitopes for recognition by 4E11 are larger than
that of DENV-1, encompassing additional A/G-strand residues that lie
outside of the core functional epitope. Furthermore, our analysis
revealed differences in recognition requirements for DENV-1 and
DENV-4 for binding to 4E5A or 4E11.
Antibody 4E5A was reported to have a 45-fold higher binding
afﬁnity for DENV-4, improved afﬁnity for DENV-2 and DENV-3, and
a slightly lower afﬁnity for DENV-1 (Tharakaraman et al., 2013). The
improved afﬁnity for DENV-4 was evident in our combinatorial
scanning data, as we were able to fully map the functional epitope
of DENV-4 DIII for 4E5A. Of the 11 fully scanned residues for 4E11
binding, only three were found to be hotspots of binding energy,
whereas for 4E5A binding, one additional hotspot residue was
identiﬁed among these 11 residues and six residues were identiﬁed
as hotspot residues in the lower half of the epitope.
For DENV-1, Tharakaraman and coworkers reported a KD value
of 0.5 nM for binding to 4E11 and a KD value of 1.8 nM for binding
to 4E5A (Tharakaraman et al., 2013). While this difference in
afﬁnity for DENV-1 is not substantial, it is interesting that our
combinatorial scanning mutagenesis analysis revealed differences
in the DENV-1 functional epitopes, with a broader functional
epitope required for 4E5A. Antibodies 4E5A and 4E11 differ by
ﬁve residues, and the mutations in 4E5A relative to 4E11 are
thought to directly contact S305, K310, E311, Q323, E327, and T329
on DENV-1. All of these residues except T329 were included in our
scanning analysis, but interestingly, substantial differences in
contribution to the antibody-antigen interface were not detected.
Instead, our results imply that the mutations in 4E5A relative to
4E11 serve to expand contributing residues on both the A- and G-
strands (increased ΔΔGAla–WT values for L308, V312, and K388 in
4E5A relative to 4E11). Thus, in this case, the designed mutations
to endow 4E5A with broader speciﬁcity also increased the con-
tributing surface area to DENV-1 in the central portion of the
structural epitope. This information could not be inferred from
previous structural or biochemical experiments on 4E11 and 4E5A.
Given recent interest in therapeutic antibodies targeting DENV DIII
(Robinson et al., 2015), the features of recognition highlighted by
our results could be used for further optimization of DIII-targeting
mAbs or of immunogens designed to elicit similar responses.
Murine-derived neutralizing antibodies with a range of speciﬁcity
proﬁles target DIII, with the A- and G-strands constituting a critical
neutralization epitope (Austin et al., 2012; Brien et al., 2010; Cockburn
et al., 2012; Edeling et al., 2014; Gentry et al., 1982; Henchal et al.,
1985; Kaufman et al., 1987; Megret et al., 1992, 2012; Roehrig et al.,
1998; Shrestha et al., 2010; Sukupolvi-Petty et al., 2007). An interest-
ing comparison arises when the previously mapped functional epitope
of murine DENV-2 mAb 1A1D-2 (Gromowski et al., 2010) is compared
to our results with 4E11. MAb 1A1D-2 is highly related to 4E11 (485%
identity in heavy and light chain Fvs), but was isolated following
immunization with DENV-2 rather than DENV-1. The structures of
1A1D-2 and 4E11 in complex with DENV-2 DIII are highly similar,
engaging similar structural epitopes. Gromowski et al. mapped the
functional epitope on 1A1D-2 by site directed mutagenesis and ELISA,
and identiﬁed K307, K310, I312, and W391 as strongly contributing
residues (Z 10-fold reduction in binding upon mutation to alanine)
and E311 and L389 among those that contributed substantially (4- to
10-fold, respectively). In addition, K307Q and K307T escape mutants
were obtained from passaging of the virus in the presence of 1A1D-2.
Many of these features are maintained in the 4E11 functional epitope
for DENV-2 mapped here, with the inclusion of L387 and L389 among
the most important contributing residues. These results illustrate that
similar, but not identical, functional epitopes may be engaged by
neutralizing antibodies that target the same structural epitope.
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Human neutralizing antibodies that arise from natural DENV
infections generally target other regions of the E glycoprotein, although
some DIII-speciﬁc humanmAbs have been described (Beltramello et al.,
2010; de Alwis et al., 2011; Wahala and de Silva, 2011; Williams et al.,
2012). Nonetheless the potency of the murine DIII mAbs has led to
signiﬁcant interest in DIII as a target for immunotherapeutic develop-
ment as well as immunogen design (Bernardo et al., 2008; Block et al.,
2010; Izquierdo et al., 2008). Due to the potential for ADE, it is beneﬁcial
to focus on bNAbs and immunogens that elicit bNAbs. Our results
suggest that requirements for broad recognition of DIII include the core
functional epitope of K310, L387, L/I389, and W391, at least for A/G-
strand-targeting antibodies. DIII vaccination studies have suggested that
recombinant DIII alone, from a single serotype, elicits mostly a
serotype-speciﬁc and non-neutralizing immune response. In one study,
the majority of elicited antibodies in response to DIII immunization
were localized to the AB loop and were poorly or non-neutralizing (Li
et al., 2013). Our analysis suggests that targeting the immune response
or therapeutic antibody design toward the critical functional core of DIII
could improve efﬁciency of bNAb development or design of immuno-
gens that elicit bNAbs.
Antibody–protein antigen interactions are prime examples of
speciﬁc protein–protein interactions that are essential to biology.
The functional requirements for most antibody–protein interactions
are presumably similar to those of most other protein–protein
interactions and involve burial of a few critical hydrophobic hot
spot residues. However, the relationship between functional
requirements for multiple antigens in multispeciﬁc antibodies
(e.g., bNAbs) has not been as clearly delineated. Our results indicate
that broad recognition of DIII by the two different but related bNAbs
4E11 and 4E5A have distinct functional epitopes despite the overall
similarity of binding. Therefore, plasticity in recognition by the
combining site is a key factor for broad recognition. Whether or not
a general set of rules can be established for bNAb recognition
remains to be determined, but the results presented herein provide
a template for at least one case.
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Materials and methods
Expression and puriﬁcation of bNAbs 4E11 and 4E5A
The hybridoma cell line for 4E11 was provided by Dr. Fernando
Arenzana-Seisdedos (Institute Pasteur, Paris). To purify 4E11 IgG,
hybridoma cell supernatants were centrifuged at high speed to
remove cell debris. 4E11 was then puriﬁed from the clariﬁed
supernatants by using protein A afﬁnity agarose beads (Pierce,
ThermoScientiﬁc, Rockford, IL) and the Gentle Antibody Elution
System (Pierce, ThermoScientiﬁc, Rockford, IL) as per manufac-
turer’s protocol. 4E11 was desalted into 150 mM HEPES and
200 mM NaCl pH¼7.4 for use in experiments. The heavy and light
chain variable domains of 4E5A were cloned into modiﬁed pMAZ-
IgH and -IgL vectors (Mazor et al., 2007). These vectors were
modiﬁed to express murine IgG2A constant domains 1, 2, and 3,
and murine kappa light chain, respectively. 4E5A IgH and IgL were
co-transfected into HEK 293F cells (Invitrogen, Grand Island, NY)
using polyethylenimine (PEI) (Polysciences, Warrington, PA), and
incubated for 5 days at 37 oC with 8% CO2. IgGs were then puriﬁed
and desalted as described above for the following experiments.
Phage display of DENV DIII
The HP153 vector was used to display the four DIII antigens on
the surface of ﬁlamentous bacteriophage (Persson et al., 2013). The
Escherichia coli codon-optimized synthetic genes for DIII from each
serotype (DENV-1: Guiana/FGA89/1989; DENV-2: Jamaica/1409/
1983; DENV-3: Thailand/PaH881/1988; DENV-4: Burma/63632/
1976) containing an N-terminal FLAG tag were obtained from
Genewiz (South Plainﬁeld, NJ). The DIII constructs were cloned into
phagemid HP153 using NsiI and FseI restriction sites. This cloning
strategy results in the bivalent display of DIII on the surface of
phage as a fusion to the minor phage coat protein pIII with an N-
terminal FLAG epitope for detection by the monoclonal antibody
M2, all under the control of the pho A promoter. Phage particles
expressing DIII were produced by separately electroporating each of
the four phagemids (corresponding to DIII from DENV-1, -2, -3, and
-4) into E. coli XL1-Blue cells and growing for 5 h at 37 oC in 2YT
media containing 10 μg/mL tetracycline and 50 μg/mL carbenicillin.
This culture was coinfected with 1010 plaque forming units (PFU) of
M13K07 helper phage for 1 h at 37 oC. 50 μg/mL of kanamycin was
then added and the culture was grown overnight at 37oC. Phage
were precipitated by addition of 4% (w/v) polyethylene glycol (PEG)
8000 and 3% (w/v) NaCl after removal of cells by centrifugation.
Precipitated phage were centrifuged and subsequently resuspended
in PBS containing 1% (w/v) BSA.
Functional display of DIII on the surface of phage was conﬁrmed
using a phage enzyme-linked immunosorbent assay (ELISA) in
which 4E11 and 4E5A were coated on Costar EIA/RIA high-binding
plates (Fisher Scientiﬁc, Nepean, ON, Canada) at 0.5 μg per well in
PBS pH¼8.0 overnight at 4 oC. All further incubations were com-
pleted at 37oC. Plates were blocked with 1% (w/v) BSA in PBS
(pH¼7.4) for 2 h. Wells were washed with PBS containing 0.05%
(v/v) Tween-20 (PBS-T) and DIII-expressing phage were then added
to the wells for 1 h. Wells were washed 5 times with PBS-T. An anti-
M13 HRP-conjugated antibody was then allowed to bind for 1 h.
The wells were washed with PBS-T and the anti-M13-HRP con-
jugate was detected using 3,30,5,50-tetramethylbenzidine (TMB)
(Sigma-Aldrich, St. Louis, MO).
Preparation of the DIII combinatorial scanning mutagenesis libraries
The structural epitope of each DIII serotype was split into two
libraries in which the residues were allowed to vary between the
wildtype (WT) identity and alanine (Ala) using degenerate codons
based on the alanine scanning code (Weiss et al., 2000). This
resulted in the production of 8 alanine-scanning libraries (two
per serotype). For DENV-1 and -2, inactive templates, in which
structural epitope residues were replaced with AGA or AGG rare
arginine codons, were produced to serve as the templates for
library synthesis. For DENV-3 and -4, the inactive template
contained TAA stop codons in place of structural epitope residues.
Kunkel mutagenesis was performed as previously described to
replace inactive rare Arg or stop codons with library DNA using 50-
phosphorylated primers listed in the Supplemental Information
(Sidhu and Weiss, 2004). Kunkel mutagenesis reactions contained
10 μg of uridine-enriched single stranded template DNA and a 3-
fold excess of each library primer. Library DNA was subsequently
puriﬁed and electroporated into high efﬁciency electrocompetent
E. coli SS320 cells to yield from 1.4107 to 5.61010 library
clones. Each library synthesis resulted in the production of library
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sizes that exceeded the theoretical diversity by at least 100-fold;
therefore, all sequences were adequately represented.
Library screening and analysis
Each alanine-scanning library (8 in total) was subjected to three
rounds of selection against 4E11 or 4E5A (functional selection) and one
to three rounds of selection against the anti-FLAG antibody, M2, to
control for display bias (display selection). For the functional selections,
each round consisted of coating seven wells with 0.5 μg of 4E11 or
4E5A and one well with PBS overnight at 4oC. Wells were blocked with
1% (w/v) BSA in PBS for 2 h and library phage were then allowed to
bind for 1 h before washing 5 times with PBS-T. Bound phage were
eluted by incubating with 100mM Glycine pH¼2.0 for 5 min at room
temperature (RT), and neutralizing with 2M Tris pH¼7.5. M2 selec-
tions were performed similarly, except seven wells were coated with a
1:500 dilution of M2 in PBS pH¼8.0 overnight. After each round of
selection, eluted phage were ampliﬁed by infecting E. coli XL1-Blue
cells, coinfecting with M13K07 helper phage and precipitated as
described above for further rounds of selection.
To analyze individual clones for binding to 4E11 and 4E5A individual
clones were grown in 1mL 2YT media supplemented with 1010 PFU
M13K07 helper phage, and 100 μg/mL carbenicillin in 96 deep-well
plates overnight at 37 oC. Cells were removed by centrifugation and the
phage-containing supernatants were applied to plates containing 4E11,
4E5A or BSA. Wells were washed 5 times with PBS-T and were
incubated with an anti-M13-HRP conjugate for 1 h. Wells were washed
with PBS-T and bound clones were detected using TMB substrate.
Clones that demonstrated an ELISA-positive signal 10-fold higher for
the 4E11 and 4E5A plates compared with the BSA control plates were
sent to Genewiz for sequencing. The M2 display sorts were performed
similarly, except thewells were coated with a 1:500 dilution of M2. The
WT/Ala ratio was calculated at each position of diversity for each library
and converted to a ΔΔG value using the equation: ΔΔG¼RT ln (WT/
Ala) for both the functional selection (4E11 or 4E5A) and the display
selection (M2) as previously described (Pál et al., 2005; Weiss et al.,
2000). ΔΔGAla–WT values were calculated as follows: ΔΔGAla–
WT¼ΔΔG (functional selection)ΔΔG (display selection).
Single point mutations and competition ELISAs
Selected single point mutations for DENV-1 and DENV-2 DIII were
prepared using Kunkel mutagenesis and the wildtype uridine-enriched
single stranded DENV-1 or DENV-2 DIII phagemid DNA (dU-ssDNA).
Mutation was conﬁrmed by sequencing individual clones. Clones
containing the correct mutations were electroporated into E. coli XL1-
Blue cells as described above. Single point mutant phage clones were
ampliﬁed and precipitated as described previously. Phage competition
ELISAs were performed to determine the binding afﬁnities to 4E11 of
the mutant DENV-1 and DENV-2 DIII phage by competing with soluble
WT DENV-1 or DENV-2 DIII, respectively. For competition ELISAs, 4E11
was coated at 0.5 μg per well overnight at 4oC. Plates were blocked
with 1% (w/v) BSA in PBS for 2 h and then washed 5 times with PBS-T.
A 1:10 dilution of mutant or WT DENV-1 and DENV-2 DIII expressing
phage was then incubated with varying concentrations of soluble WT
DENV-1 (0 to 10 μM) and DENV-2 DIII (0–20 μM) for 1 h. Plates were
washed 5 times with PBS-T and incubated with an anti-M13-HRP
conjugated antibody for 1 h. Plates were washed 5 times with PBS-T
and remaining bound phage were detected using TMB substrate. The
data was graphed using GraphPad Prism (GraphPad Software, La Jolla,
CA), IC50 values were obtained by ﬁtting the competition ELISA data to a
single phase exponential decay curve.
Production of soluble DIII protein
Soluble DENV-2 DIII protein (construct “LDIIIH1CS”) was isolated as
previously described (Liao and Kielian, 2005; Liao et al., 2010). A gene
for expression of soluble DENV-1 DIII protein was produced by
incorporating a His-8 tag and stop (TAA) codon into the DENV-1 DIII
expressing phagemid at the end of the DIII sequence just prior to the
phage pIII protein by Kunkel mutagenesis (Sidhu andWeiss, 2004). The
mutation was conﬁrmed by sequencing individual clones. Soluble
wildtype DENV-1 DIII was produced by electroporating the His-8-stop
DENV-1 DIII construct into E. coli BL21(DE3)STAR cells (Life Technolo-
gies, Carlsbad, CA). Cells were then grown in 25mL 2YTwith 100 μg/
mL Carbenicillin overnight at 37 oC. Five mL of this overnight culture
was then transferred to 100mL low phosphate media (per liter: 3.57 g
ammonium sulfate, 0.517 g sodium citrate monobasic anhydrous, 1.07 g
potassium chloride, 5.36 g Hy-Case SF Casein acid hydrolysate from
bovine milk, 5.36 g yeast extract, pH¼7.3 with KOH, after autoclaving
add 7mL 1M MgSO4 and 14mL 1M Glucose) with 100 μg/mL
Carbenicillin for 24 h at 30 oC. DENV-1 DIII was harvested by pelleting
the cells, freezing the cell pellet, and then disrupting cell membranes by
resuspending in 1 BugBuster (Novagen, Madison, WI) containing
Deoxyribonuclease I (Life Technologies, Invitrogen, Carlsbad, CA) and a
cOmplete mini EDTA-free protease inhibitor cocktail inhibitor (Life-
sciences, Roche, Indianapolis, IN) in PBS pH¼7.4. Cell debris was
pelleted by centrifugation at 16,000 rpm for 20min. DIII-containing
supernatant was then batch bound to Ni-NTA beads (Qiagen, Valencia,
CA) for 2 h at 4oC. Flow through was collected and the beads were
washed and eluted in PBS pH¼7.4 with increasing concentrations of
Imidazole (45mM, 150mM, 200mM, and 1M). Puriﬁed fractions of
DIII were determined by SDS-PAGE, pooled, concentrated, and buffer
exchanged into PBS pH¼7.4 using a 3000 molecular weight cut off
(MWCO) Amicon (Millipore, Merck KGaA, Darmstadt, Germany). DENV-
1 DIII concentration was determined by Bradford assay.
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